India Globalization Capital Inc
$ 0.28
-4.68%
09 Jun - close price
- Market Cap 28,526,000 USD
- Current Price $ 0.28
- High / Low $ 0.30 / 0.28
- Stock P/E N/A
- Book Value 0.06
- EPS -0.06
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.83 %
- 52 Week High 0.50
- 52 Week Low 0.24
About
India Globalization Capital, Inc. buys and resells physical infrastructure commodities. The company is headquartered in Potomac, Maryland.
Analyst Target Price
$4.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-03 | 2026-02-18 | 2025-11-14 | 2025-08-14 | 2025-06-27 | 2025-02-14 | 2024-11-12 | 2024-08-08 | 2024-06-24 | 2024-02-14 | 2023-11-09 | 2023-07-07 |
| Reported EPS | -0.02 | -0.02 | -0.02 | -0.0148 | -0.01 | -0.02 | -0.02 | -0.03 | -0.4 | -0.05 | -0.05 | -0.04 |
| Estimated EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 | -0.05 | 0 |
| Surprise | 0 | 0 | 0 | 0.0152 | 0.01 | 0.01 | 0.01 | 0 | -0.36 | -0.01 | 0 | -0.04 |
| Surprise Percentage | 0% | 0% | 0% | 50.6667% | 50% | 33.3333% | 33.3333% | 0% | -900% | -25% | 0% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IGC
2026-06-09 14:10:30
Ascendiant Capital Markets has increased its price target for IGC Pharma Inc. to $5.50 per share, based on the company's clinical progress and anticipated catalysts in 2026. IGC Pharma is a clinical-stage biotechnology company focused on treatments for Alzheimer's disease, with its lead candidate, IGC-AD1, currently in a Phase 2 clinical trial for agitation associated with Alzheimer's. The report suggests that further positive clinical data and advancements in the coming year could significantly boost the company's stock.
2026-06-08 20:08:55
IGC Pharma, Inc. has amended its loan agreement with O-Bank Co., Ltd., extending its existing Master Loan and Security Agreement and General Banking Facility Letter. The facility continues to provide a maximum aggregate limit of $12,000,000, with key terms largely unchanged, except for an increase in the facility fee from $48,000 to $60,000. This agreement is classified as a material definitive agreement and creates a direct financial obligation for IGC.
2026-06-08 20:08:55
IGC Pharma has extended its $12 million Master Loan and Security Agreement and General Banking Facility Letter with O-Bank. The extension maintains the maximum aggregate borrowing limit and largely keeps the terms unchanged from the 2025 letter, except for an increased facility fee of $60,000 from $48,000. This move is intended to support the company's liquidity and financial flexibility.
2026-06-02 15:11:06
IGC Pharma, Inc. has announced the addition of Icahn School of Medicine at Mount Sinai as a new clinical site for its Phase 2 CALMA trial of IGC-AD1, which is evaluating a therapeutic for agitation associated with Alzheimer's disease. This development occurs as the trial approaches completion, with approximately 80% of participants already finished. The inclusion of Mount Sinai is expected to enhance final-stage execution, patient access, and data integrity as the company moves towards database lock and topline analysis.
2026-06-02 14:39:41
IGC Pharma announced the addition of Mount Sinai as a clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The trial is nearing completion, with approximately 80% of participants having finished, and the inclusion of Mount Sinai is expected to support final-stage execution, patient access, and data integrity ahead of database lock and topline analysis. This expansion enhances the company's presence in a major metropolitan research center and provides access to a diverse patient population.
2026-06-02 14:12:38
IGC Pharma has added Mount Sinai as a clinical site for its Phase 2 CALMA trial, which is evaluating IGC-AD1 for agitation associated with Alzheimer's disease. With approximately 80% of targeted participants having completed the trial, the company is moving closer to database lock and topline analysis. The addition of Mount Sinai aims to strengthen patient access and data integrity as the trial progresses toward completion.
